On September 7, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, reported that it will participate in Citi’s 16th Annual BioPharma Virtual Conference 2021 investor conference (Press release, Novavax, SEP 7, 2021, View Source [SID1234587346]). Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Fireside Chat

Date:

Thursday, September 9, 2021

Time:

4:10 – 4:55 p.m. Eastern Time (ET)

Moderator:

Michael Guba

Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Conference

Event:

Investor meetings

Date:

Thursday, September 9, 2021

A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.